Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN514354 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Cofilin 1 (Non-Muscle) (CFL1) (AA 1-166), (full length) antibody
- Antibody type
- Monoclonal
- Reactivity
- Human
- Host
- Mouse
- Epitope
- AA 1-166, full length
- Isotype
- IgG
- Antibody clone number
- 1A1
- Vial size
- 100 μg
- Storage
- Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
- Handling
- Aliquot to avoid repeated freezing and thawing.
Submitted references Determination of urine cofilin-1 level in acute kidney injury using a high-throughput localized surface plasmon-coupled fluorescence biosensor.
Proteomic analysis of human epithelial lining fluid by microfluidics-based nanoLC-MS/MS: a feasibility study.
Identification of phosphorylated serine-15 and -82 residues of HSPB1 in 5-fluorouracil-resistant colorectal cancer cells by proteomics.
Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy.
Chang YF, Chao CH, Lin LY, Tsai CH, Chou C, Lee YJ
Journal of biomedical optics 2014 Jan;19(1):011004
Journal of biomedical optics 2014 Jan;19(1):011004
Proteomic analysis of human epithelial lining fluid by microfluidics-based nanoLC-MS/MS: a feasibility study.
Franciosi L, Govorukhina N, Fusetti F, Poolman B, Lodewijk ME, Timens W, Postma D, ten Hacken N, Bischoff R
Electrophoresis 2013 Sep;34(18):2683-94
Electrophoresis 2013 Sep;34(18):2683-94
Identification of phosphorylated serine-15 and -82 residues of HSPB1 in 5-fluorouracil-resistant colorectal cancer cells by proteomics.
Sakai A, Otani M, Miyamoto A, Yoshida H, Furuya E, Tanigawa N
Journal of proteomics 2012 Jan 4;75(3):806-18
Journal of proteomics 2012 Jan 4;75(3):806-18
Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy.
Nishimura S, Tsuda H, Kataoka F, Arao T, Nomura H, Chiyoda T, Susumu N, Nishio K, Aoki D
Human pathology 2011 Apr;42(4):516-21
Human pathology 2011 Apr;42(4):516-21
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- ELISA